Evidence map›Paper›PMID 42501316›Full record

ArticleAmerican journal of hematology2026

HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.

Marco Becilli, Francesca Del Bufalo, Pietro Merli, Chiara Rosignoli, Mattia Algeri, Monica Gunetti, Daria Pagliara, Francesco Quagliarella, Emilia Boccieri, Biancamaria Mandelli and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marco BecilliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0002-8874-4092
Francesca Del BufaloDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Pietro MerliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0001-6426-4046
Chiara RosignoliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Mattia AlgeriDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Monica GunettiOfficina Farmaceutica, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Daria PagliaraDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Francesco QuagliarellaDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Emilia BoccieriDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Biancamaria MandelliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Valentina BertainaDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0002-9028-7767
Maria Giuseppina CefaloDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Chiara AgratiDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0002-5252-0927
Matilde SinibaldiDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0001-5277-8998
Laura IaffaldanoDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Biagio De AngelisDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0002-7938-737X
Concetta QuintarelliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Franco LocatelliDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.ORCID https://orcid.org/0000-0002-7976-3654

Funding

Associazione Italiana per la Ricerca sul Cancro (AIRC), Investigator Grant (IG) 2018 ID 21724Associazione Italiana per la Ricerca sul Cancro (AIRC), Investigator Grant (IG) AIRC IG 2023 ID 29057Associazione Italiana per la Ricerca sul Cancro (AIRC), Investigator Grant (IG) MFAG 25106Blood Cancer United ACT9044-26European Union-Next Generation EU, Mission 4, Component 2 CUP B93D21010860004Fondazione Umberto Veronesi, PALM Research ProjectItalian Ministry of Health GR-2021-12 372 614Italian Ministry of Health RF-2021-12 374 120Ministero delle Imprese e del Made in Italy-POS project Life Science Hub Regione Puglia F/260019/01/04/X51Ministero dello Sviluppo Economico-Bando 2023 Filiere ProduttiveMinistero dell'Università e della Ricerca PRIN 2020Ministero dell'Università e della Ricerca PRIN 2022National Center for Gene Therapy and Drugs Based on RNA Technology PNRR-MCNT2-2023-12 378 065Next Generation EU, Mission 6, Component 2 CUP E83C24000730006
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42501316
PMCPMC13540302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.